BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ibraghimov-Beskrovnaya O, Natoli TA. mTOR signaling in polycystic kidney disease. Trends Mol Med. 2011;17:625-633. [PMID: 21775207 DOI: 10.1016/j.molmed.2011.06.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Liko D, Hall MN. mTOR in health and in sickness. J Mol Med 2015;93:1061-73. [DOI: 10.1007/s00109-015-1326-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
2 Morita M, Kanasaki K. Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells. Diabetes Metab 2020;46:353-61. [PMID: 32891754 DOI: 10.1016/j.diabet.2020.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Michgehl U, Pavenstädt H, Vollenbröker B. Cross talk between the Crumbs complex and Hippo signaling in renal epithelial cells. Pflugers Arch 2017;469:917-26. [PMID: 28612137 DOI: 10.1007/s00424-017-2004-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
4 Margaria JP, Campa CC, De Santis MC, Hirsch E, Franco I. The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium. Cell Signal 2020;66:109468. [PMID: 31715259 DOI: 10.1016/j.cellsig.2019.109468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Xu JX, Lu TS, Li S, Wu Y, Ding L, Denker BM, Bonventre JV, Kong T. Polycystin-1 and Gα12 regulate the cleavage of E-cadherin in kidney epithelial cells. Physiol Genomics 2015;47:24-32. [PMID: 25492927 DOI: 10.1152/physiolgenomics.00090.2014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
6 Gamberi C, Hipfner DR, Trudel M, Lubell WD. Bicaudal C mutation causes myc and TOR pathway up-regulation and polycystic kidney disease-like phenotypes in Drosophila. PLoS Genet 2017;13:e1006694. [PMID: 28406902 DOI: 10.1371/journal.pgen.1006694] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
7 Shillingford JM, Leamon CP, Vlahov IR, Weimbs T. Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 2012;23:1674-81. [PMID: 22859856 DOI: 10.1681/ASN.2012040367] [Cited by in Crossref: 70] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
8 Testa F, Magistroni R. ADPKD current management and ongoing trials. J Nephrol 2020;33:223-37. [PMID: 31853789 DOI: 10.1007/s40620-019-00679-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Arts HH, Knoers NV. Current insights into renal ciliopathies: what can genetics teach us? Pediatr Nephrol 2013;28:863-74. [PMID: 22829176 DOI: 10.1007/s00467-012-2259-9] [Cited by in Crossref: 69] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
10 Ko JY. Functional Study of the Primary Cilia in ADPKD. Adv Exp Med Biol 2016;933:45-57. [PMID: 27730434 DOI: 10.1007/978-981-10-2041-4_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Zimmerman KA, Hopp K, Mrug M. Role of chemokines, innate and adaptive immunity. Cell Signal 2020;73:109647. [PMID: 32325183 DOI: 10.1016/j.cellsig.2020.109647] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Fitzgibbon WR, Dang Y, Bunni MA, Baicu CF, Zile MR, Mullick AE, Saigusa T. Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade. Am J Physiol Renal Physiol 2018;314:F210-8. [PMID: 29021226 DOI: 10.1152/ajprenal.00389.2017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zimmerman K, Yoder BK. SnapShot: Sensing and Signaling by Cilia. Cell 2015;161:692-692.e1. [PMID: 25910215 DOI: 10.1016/j.cell.2015.04.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
14 Ghazi S, Polesel M, Hall AM. Targeting glycolysis in proliferative kidney diseases. American Journal of Physiology-Renal Physiology 2019;317:F1531-5. [DOI: 10.1152/ajprenal.00460.2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Walz G. Role of primary cilia in non-dividing and post-mitotic cells. Cell Tissue Res 2017;369:11-25. [PMID: 28361305 DOI: 10.1007/s00441-017-2599-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
16 Gargalionis AN, Korkolopoulou P, Farmaki E, Piperi C, Dalagiorgou G, Adamopoulos C, Levidou G, Saetta A, Fragkou P, Tsioli P. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. Int J Cancer. 2015;136:1515-1527. [PMID: 25123959 DOI: 10.1002/ijc.29140] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
17 Pan J, Seeger-Nukpezah T, Golemis EA. The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci 2013;70:1849-74. [PMID: 22782110 DOI: 10.1007/s00018-012-1052-z] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
18 Takahashi K, Nagai T, Chiba S, Nakayama K, Mizuno K. Glucose deprivation induces primary cilium formation through mTORC1 inactivation. J Cell Sci 2018;131:jcs208769. [PMID: 29180513 DOI: 10.1242/jcs.208769] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
19 Avasthi P, Maser RL, Tran PV. Primary Cilia in Cystic Kidney Disease. Results Probl Cell Differ 2017;60:281-321. [PMID: 28409350 DOI: 10.1007/978-3-319-51436-9_11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
20 Millet-Boureima C, Rozencwaig R, Polyak F, Gamberi C. Cyst Reduction by Melatonin in a Novel Drosophila Model of Polycystic Kidney Disease. Molecules 2020;25:E5477. [PMID: 33238462 DOI: 10.3390/molecules25225477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Weydert C, Decuypere JP, De Smedt H, Janssens P, Vennekens R, Mekahli D. Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models. Pediatr Nephrol 2019;34:1697-715. [PMID: 30215095 DOI: 10.1007/s00467-018-4057-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 2018;29:571-8. [PMID: 29118087 DOI: 10.1681/ASN.2017070819] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 7.4] [Reference Citation Analysis]
23 Du E, Li H, Jin S, Hu X, Qiu M, Han R. Evidence that TMEM67 causes polycystic kidney disease through activation of JNK/ERK-dependent pathways. Cell Biol Int 2013;37:694-702. [PMID: 23456819 DOI: 10.1002/cbin.10081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Armour EA, Carson RP, Ess KC. Cystogenesis and elongated primary cilia in Tsc1-deficient distal convoluted tubules. Am J Physiol Renal Physiol 2012;303:F584-92. [PMID: 22674026 DOI: 10.1152/ajprenal.00141.2012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
25 Lemoine L, Sugarbaker P, Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol 2016; 22(34): 7692-7707 [PMID: 27678351 DOI: 10.3748/wjg.v22.i34.7692] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
26 Pala R, Alomari N, Nauli SM. Primary Cilium-Dependent Signaling Mechanisms. Int J Mol Sci 2017;18:E2272. [PMID: 29143784 DOI: 10.3390/ijms18112272] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 12.8] [Reference Citation Analysis]
27 Tao F, Jiang T, Tao H, Cao H, Xiang W. Primary cilia: Versatile regulator in cartilage development. Cell Prolif 2020;53:e12765. [PMID: 32034931 DOI: 10.1111/cpr.12765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Billot K, Coquil C, Villiers B, Josselin-Foll B, Desban N, Delehouzé C, Oumata N, Le Meur Y, Boletta A, Weimbs T, Grosch M, Witzgall R, Saunier S, Fischer E, Pontoglio M, Fautrel A, Mrug M, Wallace D, Tran PV, Trudel M, Bukanov N, Ibraghimov-Beskrovnaya O, Meijer L. Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8. Am J Physiol Renal Physiol 2018;315:F57-73. [PMID: 29537311 DOI: 10.1152/ajprenal.00489.2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Kou P, Wei S, Xiong F. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open? Curr Med Chem 2019;26:2962-73. [PMID: 29600752 DOI: 10.2174/0929867325666180330094434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol 2016;27:1437-47. [PMID: 26538633 DOI: 10.1681/ASN.2015020132] [Cited by in Crossref: 77] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
31 Millet-Boureima C, Selber-Hnatiw S, Gamberi C. Drug discovery and chemical probing in Drosophila. Genome 2021;64:147-59. [PMID: 32551911 DOI: 10.1139/gen-2020-0037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Li J, Lu D, Liu H, Williams BO, Overbeek PA, Lee B, Zheng L, Yang T. Sclt1 deficiency causes cystic kidney by activating ERK and STAT3 signaling. Hum Mol Genet 2017;26:2949-60. [PMID: 28486600 DOI: 10.1093/hmg/ddx183] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
33 Zhang JQJ, Burgess J, Stepanova D, Saravanabavan S, Wong ATY, Kaldis P, Rangan GK. Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease. Lab Invest 2020;100:696-711. [PMID: 31915367 DOI: 10.1038/s41374-019-0360-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Taulet N, Delaval B. [Non-ciliary functions of cilia proteins]. Med Sci (Paris) 2014;30:1040-6. [PMID: 25388587 DOI: 10.1051/medsci/20143011019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
35 Skalická K, Hrčková G, Vaská A, Baranyaiová Á, Kovács L. Genetic defects in ciliary genes in autosomal dominant polycystic kidney disease. World J Nephrol 2018; 7(2): 65-70 [PMID: 29527510 DOI: 10.5527/wjn.v7.i2.65] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Gupta S, Ozimek-Kulik JE, Phillips JK. Nephronophthisis-Pathobiology and Molecular Pathogenesis of a Rare Kidney Genetic Disease. Genes (Basel) 2021;12:1762. [PMID: 34828368 DOI: 10.3390/genes12111762] [Reference Citation Analysis]
37 Ta MH, Schwensen KG, Foster S, Korgaonkar M, Ozimek-Kulik JE, Phillips JK, Peduto A, Rangan GK. Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease. PLoS One 2016;11:e0164193. [PMID: 27723777 DOI: 10.1371/journal.pone.0164193] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
38 Antignac C, Calvet JP, Germino GG, Grantham JJ, Guay-Woodford LM, Harris PC, Hildebrandt F, Peters DJ, Somlo S, Torres VE, Walz G, Zhou J, Yu AS. The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees. J Am Soc Nephrol 2015;26:2081-95. [PMID: 25952256 DOI: 10.1681/ASN.2014121192] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
39 Pathomthongtaweechai N, Soodvilai S, Pichyangkura R, Muanprasat C. Novel Potential Application of Chitosan Oligosaccharide for Attenuation of Renal Cyst Growth in the Treatment of Polycystic Kidney Disease. Molecules 2020;25:E5589. [PMID: 33261193 DOI: 10.3390/molecules25235589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kühn WE, Walz G. The Treatment of Autosomal Dominant Polycystic Kidney Disease. Dtsch Arztebl Int 2015;112:884-90. [PMID: 26900155 DOI: 10.3238/arztebl.2015.0884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
41 Cordido A, Besada-Cerecedo L, García-González MA. The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease-A Primer for Clinicians. Front Pediatr 2017;5:279. [PMID: 29326913 DOI: 10.3389/fped.2017.00279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
42 Lai Y, Jiang Y. Reciprocal Regulation between Primary Cilia and mTORC1. Genes (Basel) 2020;11:E711. [PMID: 32604881 DOI: 10.3390/genes11060711] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
43 Yuajit C, Muanprasat C, Gallagher AR, Fedeles SV, Kittayaruksakul S, Homvisasevongsa S, Somlo S, Chatsudthipong V. Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease. Biochem Pharmacol 2014;88:412-21. [PMID: 24518257 DOI: 10.1016/j.bcp.2014.01.038] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
44 Rogers KA, Moreno SE, Smith LA, Husson H, Bukanov NO, Ledbetter SR, Budman Y, Lu Y, Wang B, Ibraghimov-Beskrovnaya O, Natoli TA. Differences in the timing and magnitude of Pkd1 gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD. Physiol Rep 2016;4:e12846. [PMID: 27356569 DOI: 10.14814/phy2.12846] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
45 Madhivanan K, Ramadesikan S, Hsieh WC, Aguilar MC, Hanna CB, Bacallao RL, Aguilar RC. Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins. Hum Mol Genet 2020;29:1700-15. [PMID: 32391547 DOI: 10.1093/hmg/ddaa086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
46 Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol 2021;16:908-15. [PMID: 34117082 DOI: 10.2215/CJN.16871020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Jo HS, Eum WS, Park EY, Ko JY, Kim DY, Kim DW, Shin MJ, Son O, Cho SB, Park JH, Lee CH, Yeo EJ, Yeo HJ, Choi YJ, Youn JK, Cho SW, Park J, Park JH, Choi SY. Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease. BMB Rep 2017;50:460-5. [PMID: 28760196 DOI: 10.5483/bmbrep.2017.50.9.090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
48 Padovano V, Podrini C, Boletta A, Caplan MJ. Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat Rev Nephrol 2018;14:678-87. [PMID: 30120380 DOI: 10.1038/s41581-018-0051-1] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 19.0] [Reference Citation Analysis]
49 Natoli TA, Modur V, Ibraghimov-Beskrovnaya O. Glycosphingolipid metabolism and polycystic kidney disease. Cell Signal 2020;69:109526. [PMID: 31911181 DOI: 10.1016/j.cellsig.2020.109526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Nantavishit J, Chatsudthipong V, Soodvilai S. Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion. Biochemical Pharmacology 2018;154:175-82. [DOI: 10.1016/j.bcp.2018.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Radadiya PS, Thornton MM, Puri RV, Yerrathota S, Dinh-Phan J, Magenheimer B, Subramaniam D, Tran PV, Zhu H, Bolisetty S, Calvet JP, Wallace DP, Sharma M. Ciclopirox olamine induces ferritinophagy and reduces cyst burden in polycystic kidney disease. JCI Insight 2021;6:141299. [PMID: 33784251 DOI: 10.1172/jci.insight.141299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Viana SD, Reis F, Alves R. Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges. Oxid Med Cell Longev 2018;2018:3693625. [PMID: 30510618 DOI: 10.1155/2018/3693625] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]